Selection of 2′F-modified RNA aptamers against prostate-specific antigen and their evaluation for diagnostic and therapeutic applications

2013 ◽  
Vol 405 (28) ◽  
pp. 9149-9157 ◽  
Author(s):  
M. Svobodova ◽  
D. H. J. Bunka ◽  
P. Nadal ◽  
P. G. Stockley ◽  
C. K. O’Sullivan
Keyword(s):  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Rna Aptamers ◽  
Therapeutic Applications ◽  
Selection Of

Selection of RNA aptamers specific to active prostate-specific antigen

2009 ◽  
Vol 32 (3) ◽  
pp. 379-385 ◽  
Author(s):  
Sujin Jeong ◽  
Seung Ryul Han ◽  
Young Ju Lee ◽  
Seong-Wook Lee
Keyword(s):  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Rna Aptamers ◽  
Selection Of

scholarly journals Catching the Sugars: Electrochemical Aptasensors for the Detection of Cancer-Related Glycosylation Changes in Prostate-Specific Antigen

Proceedings ◽  
2020 ◽  
Vol 60 (1) ◽  
pp. 47
Author(s):  
Ana Díaz-Fernández ◽  
Rebeca Miranda-Castro ◽  
Pedro Estrela ◽  
Noemí de-los-Santos-Álvarez ◽  
María Jesús Lobo-Castañón
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
False Positives ◽  
High Rate ◽  
Enzyme Linked Immunosorbent Assay ◽  
Glycan Structure ◽  
Specific Cancer ◽  
Different Levels ◽  
Selection Of

Prostate-specific Antigen (PSA) is the biomarker that is used for prostate cancer (PCa) detection, although its lack of specificity results in a high rate of false-positives and many unnecessary biopsies. Therefore, there is a need for more specific cancer biomarkers for PCa. Recent studies have shown that the aberrant glycosylation of proteins is a common feature of the presence of cancer. In the case of prostate cancer, there are changes in core-fucose and sialic acids in the glycan structure of PSA. In this work, we describe two different strategies to direct the selection of aptamers toward the glycans of PSA. From these strategies, we identified two aptamers (PSA-1 and PSAG-1) that bind to the glycan structure of PSA with high affinity. Both aptamers were applied in the design of electrochemical aptasensors, in sandwich and direct formats, in order to detect the changes in the glycosylation of PSA. The sensors responded to different levels of PSA in serum, and they showed higher potential to discriminate clinically-meaningful PCa than the ELISA (Enzyme-linked immunosorbent assay) test used in hospitals (reducing the number of false positives), although validation on more samples is needed.

scholarly journals RETROSPECTIVE EVALUATION OF PSA DENSITY FOR SELECTION OF BIOPSY CANDIDATES WITH PROSTATE SPECIFIC ANTIGEN IN THE GRAY ZONE

2001 ◽  
Vol 92 (6) ◽  
pp. 609-614
Author(s):  
Tatsuo Tochigi ◽  
Sadafumi Kawamura ◽  
Kenji Numahata ◽  
Satoru Tokuyama ◽  
Masaaki Kuwahara ◽  
...  
Keyword(s):  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Gray Zone ◽  
Retrospective Evaluation ◽  
Psa Density ◽  
Selection Of

Selection of patients who would not require long-term prostate-specific antigen monitoring after low-dose-rate brachytherapy

Brachytherapy ◽  
2018 ◽  
Vol 17 (6) ◽  
pp. 899-905 ◽  
Author(s):  
Naoya Niwa ◽  
Kazuhiro Matsumoto ◽  
Toru Nishiyama ◽  
Yasuto Yagi ◽  
Choichiro Ozu ◽  
...  
Keyword(s):  
Dose Rate ◽  
Prostate Specific Antigen ◽  
Low Dose ◽  
Specific Antigen ◽  
Low Dose Rate ◽  
Selection Of Patients ◽  
Selection Of ◽  
Low Dose Rate Brachytherapy

scholarly journals Large discrepancy between prostate-specific antigen results from different assays during longitudinal follow-up of a prostate cancer patient

1996 ◽  
Vol 42 (4) ◽  
pp. 637-641 ◽  
Author(s):  
H L Van Duijnhoven ◽  
N C Péquériaux ◽  
J P Van Zon ◽  
M A Blankenstein
Keyword(s):  
Prostate Specific Antigen ◽  
Prostate Cancer Patient ◽  
Specific Antigen ◽  
Gel Filtration ◽  
Correlation Study ◽  
2Nd Generation ◽  
Free Psa ◽  
Value Range ◽  
Selection Of

Abstract A case is presented of a patient with stage D prostatic carcinoma, from whom a serum sample proved to be an outlier in a correlation study performed with a 2nd-generation prostate-specific antigen (PSA) assay on the Immulite system (6.4 micrograms/L) and IMx (101 micrograms/L). Clearly, the PSA result reported by Immulite was falsely low. For nine longitudinal samples, Immulite results were approximately 20-fold lower than the IMx value (range of IMx results 5-275 micrograms/L). A selection of the samples was analyzed with the ACS:180, ES-600, and IMx (all > 180 micrograms/L); Immulite, DPC Coat-A-Count IRMA, Immuno 1, AIA-pack, and Tandem-R (all <70 micrograms/L); and Immulite free PSA assay (41 micrograms/L). Gel filtration demonstrated that apart from the alpha1-antichymotrypsin (ACT) complex, no other complexes were found. However, the sample consisted of 53% free PSA (IMx). Possibly, a change of conformation of the PSA molecule resulted in a decreased binding to ACT and a reduced affinity of the antibodies used in the affected assays.

Sign in / Sign up

Export Citation Format

Share Document